pI: 9.8485 |
Length (AA): 421 |
MW (Da): 46678 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_129097)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G06470 | probable sugar phosphate/phosphate translocator |
Brugia malayi | Bm1_41895 | Solute carrier family 35 member C2 |
Candida albicans | CaO19.6480 | similar to S. cerevisiae YMD8 (YML038C) COP1 vesicle component potential nucleotide-sugar transporter |
Candida albicans | CaO19_6480 | hypothetical protein |
Candida albicans | CaO19.13834 | similar to S. cerevisiae YMD8 (YML038C) COP1 vesicle component potential nucleotide-sugar transporter |
Caenorhabditis elegans | CELE_Y47G6A.7 | Protein Y47G6A.7, isoform A |
Dictyostelium discoideum | DDB_G0304561 | transmembrane protein |
Drosophila melanogaster | Dmel_CG14971 | CG14971 gene product from transcript CG14971-RA |
Echinococcus granulosus | EgrG_000480900 | solute carrier family 35 member C2 |
Echinococcus multilocularis | EmuJ_000480900 | solute carrier family 35 member C2 |
Homo sapiens | ENSG00000080189 | solute carrier family 35 (GDP-fucose transporter), member C2 |
Loa Loa (eye worm) | LOAG_11013 | solute carrier family 35 member C2 |
Mus musculus | ENSMUSG00000017664 | solute carrier family 35, member C2 |
Neospora caninum | NCLIV_032650 | solute carrier family protein, putative |
Oryza sativa | 4340163 | Os06g0153200 |
Oryza sativa | 4324622 | Os01g0749900 |
Onchocerca volvulus | OVOC1376 |
|
Plasmodium berghei | PBANKA_1434000 | phosphate translocator, putative |
Plasmodium falciparum | PF3D7_1218400 | triose or hexose phosphate/phosphate translocator, putative |
Plasmodium knowlesi | PKNH_1438000 | transporter, putative |
Plasmodium vivax | PVX_123592 | triose or hexose phosphate/phosphate translocator, putative |
Plasmodium yoelii | PY06524 | hypothetical protein |
Saccharomyces cerevisiae | YML038C | Ymd8p |
Schistosoma japonicum | Sjp_0022410 | Solute carrier family 35 member C2, putative |
Schistosoma mansoni | Smp_066150 | solute carrier family 35 member C2 |
Schmidtea mediterranea | mk4.001715.05 | Solute carrier family 35 member C2 |
Schmidtea mediterranea | mk4.016755.01 | |
Schmidtea mediterranea | mk4.007065.02 | |
Schmidtea mediterranea | mk4.016447.00 | |
Toxoplasma gondii | TGME49_232690 | DP-fucose transporter, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
PBANKA_1434000 | Plasmodium berghei | Dispensable | plasmo |
TGME49_232690 | Toxoplasma gondii | Probably non-essential | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.